Drug Trial News

RSS

Experimental heart failure drug has little impact on exercise tolerance

Heart failure patients taking the investigational drug omecamtiv mecarbil, which has been previously shown to improve long-term outcomes, see little impact on their ability to exercise compared to a placebo, according to a study supported by the Duke Clinical Research Institute.

4 Apr 2022

Addition of alirocumab to high-intensity statin treatment reduces key measures of plaque vulnerability

Compared with a placebo, the addition of the injectable cholesterol-lowering drug alirocumab to high-intensity statin treatment in patients who have had a heart attack resulted in twofold greater reductions in three key measures of plaque vulnerability that signal risk for future cardiac events, according to research presented at the American College of Cardiology's 71st Annual Scientific Session.

3 Apr 2022

Experimental siRNA therapeutic shows promise to reduce an important driver of heart disease risk

While there are effective therapies to reduce the risk of heart disease by lowering low-density lipoprotein (LDL), or "bad" cholesterol, and other lipids, to date there are no approved treatments to lower lipoprotein(a), a lesser-known driver of heart disease risk.

3 Apr 2022

Experimental heart failure drug does not improve exercise capacity in HFrEF patients

Patients with heart failure with reduced ejection fraction (HFrEF) did not experience any improvement in their ability to exercise vigorously after taking the experimental heart failure drug omecamtiv mecarbil, in a study presented at the American College of Cardiology's 71st Annual Scientific Session.

3 Apr 2022

Patiromer lowers hyperkalemia risk in heart failure patients taking RAASi therapy

Patients taking renin-angiotensin-aldosterone system inhibitor (RAASi) medications for heart failure had significantly lower blood potassium levels when taking patiromer—a drug that helps to prevent the body from absorbing too much potassium—compared with a placebo, in a study presented at the American College of Cardiology's 71st Annual Scientific Session.

3 Apr 2022

Extension study shows mavacamten’s efficacy and safety in treating hypertrophic cardiomyopathy

Use of mavacamten, a novel cardiac myosin inhibitor, to treat people with symptomatic obstructive hypertrophic cardiomyopathy (HCM), a condition that results in excess thickening of the heart muscle, resulted in continued benefits in patient quality of life and outcomes over an extended period of time, according to interim data from the EXPLORER-HCM extension study presented at the American College of Cardiology's 71st Annual Scientific Session.

3 Apr 2022

New drug shows promise in relieving symptoms associated with hypertrophic cardiomyopathy

A new drug shows promise in providing relief to cardiomyopathy patients experiencing shortness of breath, according to late-breaking research presented today at the American College of Cardiology (ACC) Scientific Session in Washington, D.C.

3 Apr 2022

Research demonstrates potential of local siRNA delivery as COVID antiviral therapy in the lung

Scientists develop a formulation for the pulmonary administration of siRNA. The aim was to suppress the replication of SARS-CoV-2.

3 Apr 2022

Investigational drug vupanorsen reduces non-HDL cholesterol by up to 28%

The investigational drug vupanorsen reduced total levels of non-high-density lipoprotein (non-HDL) cholesterol by up to 28% in patients with high cholesterol who were already taking a cholesterol-lowering statin medication, in a study presented at the American College of Cardiology's 71st Annual Scientific Session.

3 Apr 2022

Experimental siRNA therapy reduces a key driver of heart disease risk by up to 98%

Findings from a new Cleveland Clinic-led phase 1 trial show that an experimental "gene silencing" therapy reduced blood levels of lipoprotein(a), a key driver of heart disease risk, by up to 98%.

3 Apr 2022

Experimental drug for hypertrophic cardiomyopathy reduces the need for invasive procedures, trial shows

Findings from a Cleveland Clinic-led clinical trial showed that the use of an experimental drug in severely symptomatic, hypertrophic cardiomyopathy patients significantly reduced the need for invasive procedures.

2 Apr 2022

Investigational new drug may be safe for patients with mild cognitive impairment, dementia

A small, preliminary study of an investigational new drug being studied for mild cognitive impairment and mild dementia associated with Alzheimer's disease suggests it is safe and may be associated with improvements in executive function, thinking and memory skills.

31 Mar 2022

Therapeutic antibodies against filoviruses including Ebola and Marburg

Researchers discuss the development and structural characterization of therapeutic monoclonal antibodies targeting the surface glycoprotein of filoviruses.

31 Mar 2022

NIH-sponsored trial of second COVID-19 booster shots begins enrolling adult participants

A Phase 2 clinical trial evaluating various additional COVID-19 booster shots has begun enrolling adult participants in the United States.

31 Mar 2022

Clinical trials for experimental HIV vaccines based on mRNA technology begin in United States

Scientists urge African leaders to demand fair licensing following clinical trials of an HIV vaccine candidate.

30 Mar 2022

A ferritin nanoparticle candidate vaccine for COVID

In a recent study published on the bioRxiv* preprint server, the immunogenicity, and effectiveness of SARS-CoV-2 spike ferritin nanoparticle (SpFN) adjuvanted with aluminum hydroxide (AlOH3) or Army Liposomal Formulation QS-21 (ALFQ) in a cynomolgus macaque (CM) COVID-19 model was evaluated.

30 Mar 2022

How malaria drugs could play a part in treating chemotherapy-resistant head and neck cancers

In this interview, we speak to Kirill Kiselyov, Ph.D, and Umamaheswar Duvvuri, M.D, Ph.D, from the University of Pittsburgh, about their latest research into hydroxychloroquine, a drug widely used to prevent and treat malaria, as a potential treatment for head and neck cancers.

28 Mar 2022

New trial examines the effectiveness of a two-pronged immunotherapy for glioblastomas

A new clinical trial at the University of Cincinnati is studying the effectiveness of a new two-pronged immunotherapy treatment procedure to treat the most aggressive and deadly type of brain tumors, called glioblastomas. Originating from healthy brain cells, glioblastomas can form in any area of the brain.

25 Mar 2022

Hydrocortisone does not prevent bronchopulmonary dysplasia in preterm infants

Hydrocortisone is no more effective than placebo at preventing damage that can result from oxygen and ventilator therapy necessary to keep preterm infants alive, according to research funded by the National Institutes of Health.

23 Mar 2022

Mount Sinai launches phase 1 study to evaluate the safety, immunogenicity of egg-based COVID-19 vaccine

A team of clinical investigators at the Icahn School of Medicine at Mount Sinai has announced the launch of a Phase 1, open-label, placebo-controlled study to evaluate the safety and immunogenicity of an egg-based COVID-19 vaccine in healthy, vaccinated adults who have never been infected with COVID-19.

21 Mar 2022

Previous
1
...
48
49
50
51
52
53
54
...
1156
Next

Drug Trial News

Experimental heart failure drug has little impact on exercise tolerance

Addition of alirocumab to high-intensity statin treatment reduces key measures of plaque vulnerability

Experimental siRNA therapeutic shows promise to reduce an important driver of heart disease risk

Experimental heart failure drug does not improve exercise capacity in HFrEF patients

Patiromer lowers hyperkalemia risk in heart failure patients taking RAASi therapy

Extension study shows mavacamten’s efficacy and safety in treating hypertrophic cardiomyopathy

New drug shows promise in relieving symptoms associated with hypertrophic cardiomyopathy

Research demonstrates potential of local siRNA delivery as COVID antiviral therapy in the lung

Investigational drug vupanorsen reduces non-HDL cholesterol by up to 28%

Experimental siRNA therapy reduces a key driver of heart disease risk by up to 98%

Experimental drug for hypertrophic cardiomyopathy reduces the need for invasive procedures, trial shows

Investigational new drug may be safe for patients with mild cognitive impairment, dementia

Therapeutic antibodies against filoviruses including Ebola and Marburg

NIH-sponsored trial of second COVID-19 booster shots begins enrolling adult participants

Clinical trials for experimental HIV vaccines based on mRNA technology begin in United States

A ferritin nanoparticle candidate vaccine for COVID

How malaria drugs could play a part in treating chemotherapy-resistant head and neck cancers

New trial examines the effectiveness of a two-pronged immunotherapy for glioblastomas

Hydrocortisone does not prevent bronchopulmonary dysplasia in preterm infants

Mount Sinai launches phase 1 study to evaluate the safety, immunogenicity of egg-based COVID-19 vaccine

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News